Compare Perseus Proteomics, Inc. with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses. Due to this company has reported negative ROE
2
Poor long term growth as Net Sales has grown by an annual rate of 20.34% and Operating profit at -18.97% over the last 5 years
3
Risky -
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
JPY 2,272 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-1.40
-81.05%
2.57
Revenue and Profits:
Net Sales:
32 Million
(Quarterly Results - Mar 2026)
Net Profit:
-170 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-24.07%
0%
-24.07%
6 Months
-25.45%
0%
-25.45%
1 Year
-59.8%
0%
-59.8%
2 Years
-62.04%
0%
-62.04%
3 Years
-43.06%
0%
-43.06%
4 Years
-58.06%
0%
-58.06%
5 Years
-79.63%
0%
-79.63%
Perseus Proteomics, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
20.34%
EBIT Growth (5y)
-18.97%
EBIT to Interest (avg)
-725.94
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.16
Sales to Capital Employed (avg)
0.08
Tax Ratio
0.27%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.40
EV to EBIT
-3.45
EV to EBITDA
-3.46
EV to Capital Employed
-7.57
EV to Sales
18.92
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-81.05%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
32.40
42.10
-23.04%
Operating Profit (PBDIT) excl Other Income
-171.60
-173.50
1.10%
Interest
0.00
0.00
Exceptional Items
-6.30
-4.20
-50.00%
Consolidate Net Profit
-170.30
-168.40
-1.13%
Operating Profit Margin (Excl OI)
-5,295.00%
-4,119.90%
-117.51%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -23.04% vs 12.27% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -1.13% vs 17.17% in Dec 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
135.50
120.40
12.54%
Operating Profit (PBDIT) excl Other Income
-744.60
-826.90
9.95%
Interest
0.00
0.00
Exceptional Items
-43.30
-72.50
40.28%
Consolidate Net Profit
-718.10
-904.80
20.63%
Operating Profit Margin (Excl OI)
-5,497.50%
-6,892.60%
139.51%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 12.54% vs 19.92% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is 20.63% vs 18.08% in Mar 2025
About Perseus Proteomics, Inc. 
Perseus Proteomics, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






